Digital Health, Medtech and AI
Medtech and digital health (including AI enabled) technologies are rapidly changing how care is delivered and how health systems operate. Yet getting these products to market remains complex — reimbursement routes and procurement mechanisms are often not designed innovative technologies in mind, and navigating them can be challenging for manufacturers and payers alike.
Zeumed has worked across this space — with companies seeking funded market access across Europe and the Gulf, and with payers and governments designing frameworks to assess and fund technologies that don't fit standard procurement models.
FOR INNOVATORS
Building products that can be funded and scaled
Digital health and medtech teams may discover too late that their funding route is unclear, their evidence doesn't meet payer requirements, or their product design doesn't fit clinical procurement constraints.
We work with manufacturers to resolve these questions early — when product decisions are still reversible.
This work includes:
-
Identifying the most viable reimbursement channel for a product
-
Assessing whether the evidence will support the price you need
-
Outcome measurement design aligned to payer acceptance criteria
-
Funding flow and procurement analysis across target markets
FOR PAYORS AND GOVERNMENT
Frameworks for assessing and funding digital technologies
Payers are increasingly faced with coverage decisions on digital health and medtech products, and often find themselves relying on assessment frameworks designed for innovative medicines — frameworks that don't account for how these technologies generate value.
This work includes:
-
Mapping assessment routes and coverage mechanisms for digital health and medtech products
-
Developing case studies and reference examples to support coverage decisions
-
Economic modelling of innovative technologies to inform payer decisions
-
Supporting negotiations and conversations with manufacturers on pricing and evidence
OUR WORK
Selected Engagements
Reimbursement viability assessment for a medtech company moving from consumer to clinical markets
A consumer health technology company sought to understand whether its product could be reimbursed as a medical device. Zeumed assessed the company's clinical data, identified the most viable reimbursement channel, and used simulation modelling to evaluate the optimal price point. We identified a gap between the outcome measures being collected and those required for payer acceptance, advised on redesigning evidence generation prior to submission.
Pricing and reimbursement framework for digital health and AI-enabled technologies
Zeumed designed a full pricing and reimbursement framework for a national insurer covering the breadth of digital health technologies — from wearables and remote monitoring to virtual wards, robotics, and AI-enabled clinical decision support. The framework established assessment criteria, evidence requirements, and funding mechanisms for technology categories where standard reimbursement and procurement models do not apply.
White paper: making the investment case for a national digital health strategy
Zeumed was commissioned to develop a white paper making the investment case for a government's national digital health strategy. The paper argued for health data infrastructure as a long-term economic and system asset: setting out the conditions under which investment generates returns, how a national health intelligence system creates value beyond direct clinical outcomes, and the governance arrangements required to sustain it.
Working with digital health and medtech product teams
For innovators who need technical and economic design integrated from the start, Zeumed works in structured partnerships with specialist product and engineering teams. See how we structure this work →
Get in Touch
We welcome enquiries from innovators and payers working on digital health adoption and funding.